Thermo Fisher Scientific Recognized for Digital Innovation in Clinical Research Services

Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company’s continued investment in digital innovation across the clinical development continuum.

The recognition highlights the strength of Thermo Fisher’s PPD™ clinical research business, which is recognized for its capabilities in clinical development, patient engagement, and digital evolution in pharmacovigilance and regulatory affairs. The independent study, conducted by Information Services Group (ISG), evaluates leading providers based on technology innovation, portfolio strength and competitive positioning.

“This recognition affirms our leadership as a global CRO advancing digital clinical trials through AI and data-driven innovation across every stage of development,” said Krishna Cheriath, vice president, head of clinical research digital and AI, biopharma services, Thermo Fisher Scientific. “We are focused on building a more connected, patient-centric and AI-enabled future for clinical research that helps our customers accelerate the delivery of safe and effective therapies to patients worldwide.”

“The PPD clinical research business exemplifies the next-generation CRO model, where operational scale is enhanced by data, AI and patient-centric design to deliver predictable, high-quality clinical outcomes at global scale,” said ISG Lead Analyst Sneha Jayanth.